May 5 is World PH Day. Pulmonary hypertension (PH) often appears in public view as a rare disease. It is a fatal cardiovascular disease, referred to as "cancer in cardiovascular system". Dyspnea, shortness of breath, suffocation and hemoptysis are common symptoms of the disease. PH patients have blue-purple lips due to lack of oxygen, so the disease is also known as "Blue Lip".
Due to low social awareness, the rate of missed diagnosis and misdiagnosis of PH is high. Many patients face delay in treatment during the long process of seeking diagnosis, and are diagnosed only after the disease progresses to a later stage, resulting in poor treatment effect. Without systematic and regular treatment after diagnosis, the survival time of patients is only about 2.8 years.
In recent years, with the application of targeted drugs, the prognosis of PH patients has been gradually improved, but there are few drugs available for clinical selection, and most of the therapeutic drugs approved for marketing in China are imported, imposing a high treatment cost on patients and their families. Ambrisentan, as one of the specific drugs for targeted treatment of PH, has definite curative effect and good safety, and is recommended as a Class 1 drug in clinical medication guidelines at home and abroad. In order to solve the medication problem and ensure effective clinical supply, Hansoh Pharma has tackled various difficulties and launched the first domestic PH targeted drug, Ambrisentan Tablets (Punuoan). The successful first generic of Punuoan has effectively alleviated the dependence of patients on imported drugs.
Addressing the payment difficulties faced by patients, Hansoh Pharma and Huilan Foundation have launched an assistance program to reduce the annual treatment cost of patients by about two-thirds compared with the use of the original drug. Up to now, nearly 30,000 patients have received assistance and benefited from the program. As a high-quality domestic ambrisentan tablet that has passed the consistency evaluation, Hansoh Pharma's Punuoan was selected for the national centralized drug procurement in January 2020, which can reduce the monthly cost of patients' use of ambrisentan alone from several thousand yuan to several hundred yuan, significantly improving the drug accessibility and the possibility of combined medication, and effectively solving the "poverty caused by illness" of patients' families.
As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma will, in line with its corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", accelerate the pace of scientific and technological innovation, adhere to the orientation towards patients' benefits, and commit itself to meeting the unmet clinical needs through continuous innovation so as to benefit more patients.
